India, Jan. 12 -- Researchers from SAHMRI, SA Pathology and the University of Adelaide have developed a new, highly targeted therapeutic approach that could significantly improve outcomes for people living with myelofibrosis, a rare and serious form of blood cancer.

The research, published in the leading international journal Blood, focuses on treating myelofibrosis by directly targeting the abnormal blood cells that drive the disease through immunotherapy, rather than merely managing its symptoms.

Myelofibrosis disrupts the body's ability to produce healthy blood cells, leading to chronic fatigue, pain, an enlarged spleen and a reduced quality of life. While existing treatments can help ease symptoms, they do not eliminate the underlyi...